# Pulmonx Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Pulmonx Corp).

## Overview

Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients. Its portfolio centers on the Zephyr Endobronchial Valve, supported by the Chartis assessment system, LungTraX patient identification software, and the AeriSeal System under development and clinical evaluation.

## Products & services

• Zephyr Endobronchial Valve for bronchoscopic lung volume reduction
• Delivery catheters and related implantation accessories
• Chartis System: balloon catheters, console, and usage fees
• LungTraX Platform for identifying eligible patients
• AeriSeal System for collateral ventilation closure

- **Zephyr Valve therapy** (80%) — Endobronchial valves and delivery tools used to treat severe emphysema.
- **Chartis assessment system** (12%) — Diagnostic and procedural tools used to assess collateral ventilation and guide treatment.
- **Digital patient identification** (0%) — LungTraX software used to identify patients who may be eligible for Zephyr treatment.
- **AeriSeal program** (8%) — Synthetic polymer foam system under clinical development for lung lobe occlusion.

- Zephyr Endobronchial Valve for bronchoscopic lung volume reduction
- Delivery catheters and related implantation accessories
- Chartis System: balloon catheters, console, and usage fees
- LungTraX Platform for identifying eligible patients
- AeriSeal System for collateral ventilation closure

## Customers

Pulmonx sells primarily to hospitals, interventional pulmonologists, and distributors that support bronchoscopic lung volume reduction procedures. Demand depends on physician adoption, hospital program development, reimbursement access, and the number of patients identified as eligible for treatment. The company also works with patient advocacy and education channels to expand awareness among COPD patients and referring clinicians.

- **Hospitals and health systems** (primary) — Buy valves, catheters, and Chartis tools to establish and expand emphysema treatment programs.
- **Interventional pulmonologists** (primary) — Use the system in procedures and drive clinical adoption through patient selection and treatment.
- **International distributors** (secondary) — Purchase and resell products in select markets where direct sales are not used.
- **Patients and referring clinicians** (secondary) — Influence demand through diagnosis, referral, and awareness of minimally invasive treatment options.

- Hospitals building emphysema or interventional pulmonary programs
- Interventional pulmonologists performing Zephyr Valve procedures
- Third-party distributors in select international markets
- Patients with severe emphysema who are candidates for treatment
- Physician and patient education partners that influence adoption

## Geography

Pulmonx is headquartered in the United States and sells through a direct commercial organization there, while international markets use a mix of direct and distributor-based sales. Management discloses meaningful revenue from both the United States and international markets, with international sales spanning Europe, Asia Pacific, and other select countries. Geography matters because reimbursement, physician training, and regulatory approval differ by market and affect adoption speed.

- **United States** (64%) — Estimated from disclosed U.S. revenue of $29.0m out of $46.4m for 1H25.
- **International** (36%) — Estimated from disclosed international revenue of $17.4m out of $46.4m for 1H25.

- United States is the core commercial market and direct-sales base
- International sales are split between direct and distributor channels
- Europe is important for reimbursement-backed adoption
- Asia Pacific and other markets add growth but require local execution
- Foreign currency movements affect reported international revenue

## Strategy

Pulmonx is focused on expanding Zephyr Valve adoption by building hospital programs, training physicians, and increasing patient awareness in severe emphysema. It also seeks to broaden its addressable market through clinical evidence, regulatory work, and next-generation products such as AeriSeal, while extending commercial reach in international markets where reimbursement is established or improving.

- **Expand U.S. procedure volumes** (short-term) — The core growth lever is broader physician and hospital adoption of Zephyr Valve therapy.
- **Strengthen reimbursement and clinical evidence** (medium-term) — Coverage and published outcomes are critical for hospital uptake and payer acceptance.
- **Expand international commercialization** (medium-term) — International markets provide additional procedure volume but require local execution and reimbursement readiness.
- **Develop next-generation products** (long-term) — Pipeline expansion can increase the addressable market and reduce reliance on one product family.

- Expand Zephyr Valve adoption through hospital program development
- Train physicians and build centers of excellence for emphysema care
- Use clinical data and education to support reimbursement and adoption
- Grow direct sales in the U.S. and selected international markets
- Advance AeriSeal and other pipeline products to widen the market

## Risks

Pulmonx is exposed to adoption risk because its business depends heavily on one core therapy, physician training, and hospital program development. It also faces reimbursement, regulatory, clinical evidence, and international execution risks, all of which can slow procedure growth or limit market access. As a medical device company, it must also manage product liability, cybersecurity, and foreign exchange exposure across markets.

- **Product concentration** [high] — Substantially all revenue comes from a limited set of products, especially Zephyr Valve.
- **Reimbursement dependence** [high] — Procedures require coding, coverage, and payment support to be broadly adopted.
- **Limited commercial experience** [medium] — The company states it has limited experience marketing and selling its solution.
- **International execution** [medium] — Markets outside the U.S. require local reimbursement, regulatory, and channel management.
- **Clinical and product liability** [high] — The therapy is used in invasive procedures on high-risk COPD patients.

- Heavy reliance on Zephyr Valve creates product concentration risk
- Adoption depends on physician training and hospital program build-out
- Reimbursement and coverage can delay or limit procedure volumes
- International sales face regulatory, distributor, and FX risks
- Clinical, product liability, and cybersecurity risks are material

## Accounting

Pulmonx’s reported results are sensitive to revenue timing from procedure-based product sales, distributor shipments, and usage fees tied to the Chartis system. Seasonality is also important because the procedure is elective and management notes stronger or weaker quarters depending on holidays, vacations, and case timing. Investors should also watch estimates around revenue recognition, lease obligations, debt, and any future impairment or clinical-development related judgments.

- **Revenue recognition** — Can shift revenue between periods depending on shipment and usage timing.
- **Seasonality** — Quarterly revenue and margins may not be directly comparable.
- **Lease accounting** — Impacts liabilities, expense recognition, and liquidity analysis.
- **Debt and financing obligations** — Affects leverage, interest expense, and covenant monitoring.
- **Clinical-development and regulatory estimates** — Can affect capitalization, expense timing, and future asset values.

- Revenue timing depends on product shipment and procedure volume
- Chartis usage fees and console sales add complexity to revenue recognition
- Seasonality affects quarter-to-quarter comparability
- Lease obligations and debt affect balance sheet estimates
- Clinical development and product expansion may create judgment areas

---

*Last updated: 2026-04-29T04:50:02.379347+00:00*